A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors

Overview of attention for article published in Breast Cancer Research and Treatment, March 2016

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (67th percentile)
Good Attention Score compared to outputs of the same age and source (78th percentile)

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,691 followers.

#oa: P1 Trial of a Protein-Based Immunotherapeutic for the Treatment of BrC Patients w/ HER2-Overexpressing Tumors https://t.co/tbRPxx2ghE

A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment… https://t.co/jwjsN1qDUh #breastcancer

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.